Chapters

Transcript

Hypertrophic cardiomyopathy guideline update: Mayo Clinic's perspective

Mayo Clinic medical experts in hypertrophic cardiomyopathy, Jeffrey B. Geske, M.D., Steve R. Ommen, M.D., and Hartzell V. Schaff, M.D., discuss the recent publication of the "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy." They review the top changes to the guideline, including the introduction of a cardiac myosin inhibitor, mavacamten, for support of people with symptomatic obstructive hypertrophic cardiomyopathy (HCM); the evolved guidelines for healthy levels of exercise; the formal split in sudden cardiac death risk assessment between children and adults living with HCM; and new advice on more frequent screening for individuals who have risk factors for atrial fibrillation. For more information, visit Mayo Clinic Medical Professionals – Cardiovascular Diseases.


Published

August 2, 2024

Created by

Mayo Clinic

Related Presenters

Jeffrey B. Geske, MD

Jeffrey B. Geske, MD

Cardiologist, Echocardiographer, Internist

Jeffrey B. Geske, M.D., is a consultant in the Department of Cardiovascular Medicine at Mayo Clinic. He is interested in use of multimodality imaging to assess structural heart disease, including hypertrophic cardiomyopathy and valvular ...

View full profile

Steve R. Ommen, MD

Steve R. Ommen, MD

Cardiologist

Steve R. Ommen, M.D., is a board-certified cardiologist with special interest in hypertrophic cardiomyopathy (HCM) and valvular heart disease. His undergraduate degree is in biomedical engineering from Northwestern University in Evanston, ...

View full profile

Hartzell V. Schaff, MD

Hartzell V. Schaff, MD

Cardiovascular Surgeon

Conditions treated Congenital heart disease Coronary artery disease Heart valve disease Hypertrophic cardiomyopathy Procedures performed Aortic arch replacement Aortic root surgery Aortic valve repair and replacement Apical ...

View full profile